News
Total 4 articles
-
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
넶28 2025-01-22 -
Tirzapatide approved by FDA as first sleep apnea medication
FDA has approved Zepbound (tirzepatide) as the first and only prescription medication for adults with moderate-to-severe obstructive sleep apnea and obesity.
넶34 2025-01-21 -
Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen
Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.
넶8 2025-01-22
Better Health with ALVANTIS Peptide
Facilities
Contact
Shenzhen Alvantis Pharmaceutical Co., Ltd.
Address: Room 1902, Building D3, Nanshan Wisdom Park, No.1001, Xueyuan Avenue, Nanshan District, Shenzhen
E-mail:info@xinspharma.com
Products
